NYSE$BDX
Becton Dickinson & Co. · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
BD reported mixed Q4 2022 results with a decrease in revenue but an increase in EPS, driven by base revenue growth and strategic execution.
BD reported Q4 revenue of $4.761 billion, a decrease of 1.8% as reported, but an increase of 2.3% on a currency-neutral basis. The revenue performance was driven by a base revenue growth of 4.2% as reported, and 8.6% currency-neutral. GAAP diluted EPS was $0.92 and adjusted diluted EPS was $2.75. The company issued FY23 guidance and announced its 51st consecutive year of dividend increases, raising the dividend by 4.6%.
- Q4 revenue decreased by 1.8% as reported, but increased by 2.3% on a currency-neutral basis.
- Base revenue growth was 4.2% as reported and 8.6% on a currency-neutral basis.
- GAAP diluted EPS was $0.92, while adjusted diluted EPS was $2.75.
- FY23 revenue is expected to be in the range of $18.6 billion to $18.8 billion.
Headline financials
Revenue & EPS history
BD · Revenue · Quarterly
$4.76B
Revenue by segment
BD · $2.38B total across 2 segments · Q4 2022
- BD Life Sciences$1.29B—54.0%
- BD Interventional$1.1B—46.0%
Forward guidance
The company expects fiscal year 2023 revenues to be in the range of approximately $18.6 billion to $18.8 billion and adjusted diluted EPS to be $11.85 to $12.10.
Tailwinds
- Revenue guidance assumes base business currency-neutral revenue growth of 5.25% to 6.25%.
- Base business revenue guidance reflects continued momentum as we execute our BD 2025 growth strategy.
- Base business revenue guidance includes an anticipated impact of approximately 100 basis points from an acceleration of our simplification and RECODE programs related to planned strategic portfolio exits.
- This impact is expected to be fully offset by the positive contribution of approximately 100 basis points from the full-year benefit of recent acquisitions, primarily Parata Systems.
- The company expects adjusted diluted EPS growth of approximately 9% to 11% on a currency-neutral basis.
Headwinds
- Revenue guidance assumes approximately $125 to $175 million in COVID-19-only diagnostic testing revenues.
- Foreign exchange would represent a reduction of approximately 450 basis points to total company revenue growth.
- This includes an estimated impact from foreign currency of approximately 420 basis points based on current rates.
- The company's expected adjusted diluted EPS for fiscal 2023 excludes potential charges or gains that may be recorded during the fiscal year.
- The impact and timing of these potential charges or gains is inherently uncertain and difficult to predict and is unavailable without unreasonable efforts.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2022
-0.9%
Avg return
Earnings day
-0.9%
Avg return
5 days after
-0.5%
Avg return
30 days after
38%
28 / 73 earnings
Positive
+8.9%
Q3 2025
Best reaction
-18.1%
Q2 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | -0.7% | -1.1% | +4.6% | |
| Q1 2026 | -1.3% | +6.5% | -1.2% | |
| Q4 2025 | +0.6% | +7.2% | +10.0% | |
| Q3 2025 | +8.9% | +13.1% | +11.6% | |
| Q2 2025 | -18.1% | -20.3% | -16.7% | |
| Q1 2025 | -6.3% | -5.3% | -5.3% | |
| Q4 2024 | -3.5% | -3.7% | -8.3% | |
| Q3 2024 | +0.3% | -2.3% | +0.6% | |
| Q2 2024 | +0.4% | +1.5% | -0.7% | |
| Q1 2024 | -0.7% | -0.1% | -1.5% | |
| Q4 2023 | -8.3% | -8.8% | -9.2% | |
| Q3 2023 | -2.0% | +1.8% | +0.8% | |
| Q2 2023 | -3.8% | -5.3% | -4.5% | |
| Q1 2023 | -3.3% | -0.4% | -6.7% | |
| Q4 2022 | +4.3% | +1.9% | +13.4% | |
| Q3 2022 | +3.8% | +4.2% | +3.2% | |
| Q2 2022 | +1.7% | -1.4% | -0.5% | |
| Q1 2022 | +4.7% | +7.7% | +7.3% | |
| Q4 2021 | -1.3% | -1.4% | -1.2% | |
| Q3 2021 | -5.4% | -6.3% | +1.2% | |
| Q2 2021 | -4.2% | -3.4% | -3.6% | |
| Q1 2021 | -2.4% | -2.6% | -5.5% | |
| Q4 2020 | -0.1% | +1.5% | +2.5% | |
| Q3 2020 | -9.5% | -10.0% | -17.4% | |
| Q2 2020 | -1.8% | +1.1% | -6.6% | |
| Q1 2020 | -13.7% | -10.3% | -16.4% | |
| Q4 2019 | -3.8% | -6.1% | -0.7% | |
| Q3 2019 | +3.5% | +7.6% | +9.4% | |
| Q2 2019 | -3.0% | -4.1% | +2.6% | |
| Q1 2019 | -1.7% | -2.0% | -0.2% | |
| Q4 2018 | -0.2% | +2.5% | +1.6% | |
| Q3 2018 | -1.1% | -0.8% | +4.7% | |
| Q2 2018 | -2.4% | -3.8% | -2.3% | |
| Q1 2018 | -1.3% | -3.4% | -0.6% | |
| Q4 2017 | +7.9% | +6.3% | +8.8% | |
| Q3 2017 | -1.9% | -2.1% | -0.9% | |
| Q2 2017 | -1.4% | -0.5% | +3.5% | |
| Q1 2017 | +0.2% | -0.1% | +3.2% | |
| Q4 2016 | +4.9% | +7.1% | -0.8% | |
| Q3 2016 | -1.2% | -0.9% | +0.9% | |
| Q2 2016 | +2.0% | — | — | |
| Q1 2016 | -4.9% | — | — | |
| Q4 2015 | +3.8% | — | — | |
| Q3 2015 | -3.2% | — | — | |
| Q2 2015 | +0.7% | — | — | |
| Q1 2015 | +2.4% | — | — | |
| Q4 2014 | -0.2% | — | — | |
| Q3 2014 | -2.8% | — | — | |
| Q2 2014 | -0.4% | — | — | |
| Q1 2014 | +1.8% | — | — | |
| Q4 2013 | +0.5% | — | — | |
| Q3 2013 | -2.1% | — | — | |
| Q2 2013 | +4.1% | — | — | |
| Q1 2013 | +3.2% | — | — | |
| Q4 2012 | -4.3% | — | — | |
| Q3 2012 | -1.1% | — | — | |
| Q2 2012 | +0.0% | — | — | |
| Q4 2011 | -4.6% | — | — | |
| Q1 2012 | +1.2% | — | — | |
| Q3 2011 | -2.6% | — | — | |
| Q2 2011 | -1.0% | — | — | |
| Q1 2011 | -0.5% | — | — | |
| Q4 2010 | +2.0% | — | — | |
| Q3 2010 | +1.6% | — | — | |
| Q2 2010 | -2.6% | — | — | |
| Q1 2009 | +0.5% | — | — | |
| Q1 2010 | -1.4% | — | — | |
| Q4 2007 | -1.2% | — | — | |
| Q2 2009 | -1.2% | — | — | |
| Q4 2009 | -1.2% | — | — | |
| Q3 2009 | +2.5% | — | — | |
| Q3 2008 | +2.5% | — | — | |
| Q4 2008 | +2.5% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro